Li Zhen Zeng

20120321553, Dec 20, 2012

May 1, 2012

13/461307

Li Zeng - Edison NJ, US
Rohini Mitra - Brigdewater NJ, US
Edmund A. Rossi - Woodland Park NJ, US
Hans J. Hansen - Picayune MS, US
David M. Goldenberg - Mendham NJ, US

IMMUNOMEDICS, INC. - Morris Plains NJ

A61K 39/395
A61P 37/00
A61P 31/00
A61P 35/00
A61P 3/00
A61P 25/28
A61P 3/10
A61P 9/00
A61P 25/00
A61K 51/00
A61P 35/02

424 111, 4241301, 4241411, 4241361, 4241331, 4241781, 4241341, 424 851, 424 852, 424 854, 424 857, 424 856, 424 855, 4241581, 4241721, 4241381

Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.

63070197, Oct 23, 2001

Jul 10, 1997

8/890865

Franklin Constantini - New York NY
Li Zeng - New York NY

The Trustees of Columbia University in the City of New York - New York NY

C07K 1400
C07H 2102
C07H 2104
C12P 2106

530350

This invention provides an isolated nucleic acid which encodes Axin. This invention further provides an isolated nucleic acid which encodes a polypeptide comprising the amino acid sequence of Axin. This invention further provides a purified wildtype or mutant Axin. This invention further provides an oligonucleotide capable of distinguishing nucleic acids encoding mutant or wildtype Axin. This invention also provides various methods of use: such as a method for determining whether a subject carries a mutation in the axin gene, a method of determining whether a subject has a predisposition for cancer, a method for treating a subject who has a predisposition to cancer, a method for determining whether a subject has cancer, a method for detecting a mutation in cancerous cells of the subject, a method of suppressing cells unable to regulate themselves and a method for identifying a chemical compound which is capable of suppressing cells unable to regulate themselves. This invention also provides a variety of pharmaceutical compositions and a method of treating a subject who has cancer comprising administration the pharmaceutical compositions. This invention also provides a transgenic, nonhuman mammal, specifically a transgenic expressing mutant Axin.